APO RESEARCH · REPORT
Drugs for Herpes Labialis (Oral Herpes)
Herpes Labialis (Oral Herpes) is a type of herpes simplex occurring on the lip, i.e. an infection caused by herpes simplex virus (HSV). An outbreak typically causes small blisters or sores on or around the mouth. The sores typically heal within 2–3 weeks, but the herpes virus remains dormant in the facial nerves, following orofacial infection, periodically reactivating (in symptomatic people) to create sores in the same area of the mouth or face at the site of the original infection.
Product & engineering
Understand the product.
Herpes Labialis (Oral Herpes) is a type of herpes simplex occurring on the lip, i.e. an infection caused by herpes simplex virus (HSV). An outbreak typically causes small blisters or sores on or around the mouth. The sores typically heal within 2–3 weeks, but the herpes virus remains dormant in the facial nerves, following orofacial infection, periodically reactivating (in symptomatic people) to create sores in the same area of the mouth or face at the site of the original infection.
Selected research
Industry Research
Drugs for Herpes Labialis (Oral Herpes) Industry Research Report 2026
Market perspective
Herpes Labialis (Oral Herpes) is a type of herpes simplex occurring on the lip, i.e. an infection caused by herpes simplex virus (HSV). An outbreak typically causes small blisters or sores on or around the mouth. The sores typically heal within 2–3 weeks, but the herpes virus remains dormant in the facial nerves, following orofacial infection, periodically reactivating (in symptomatic people) to create sores in the same area of the mouth or face at the site of the original infection.
Global Drugs for Herpes Labialis (Oral Herpes) key players include GSK, Novartis, Teva, Mylan, Cadila, etc. Global top five manufacturers hold a share about 55%. North America is the largest market, with a share about 35%, followed by Europe, with a share about 30 percent. In terms of product, Rx Drugs is the largest segment, with a share about 90%. And in terms of application, the largest application is Oral, followed by External Use, and Injection, etc.
Report Scope
Read the full market overview
This report quantifies the global Drugs for Herpes Labialis (Oral Herpes) market in terms of revenue (US$ million) and, where applicable, service volume (K MT), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K MT) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Drugs for Herpes Labialis (Oral Herpes).
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Drugs for Herpes Labialis (Oral Herpes) Market by Company
GSK
Novartis
Teva
Mylan
Cadila
Apotex
Daewoong Pharmaceutical
Livzon
Luoxin
Med shine
Bayer (Campho Phenique)
Blistex
Kelun
Hikma
Haiwang
Carmex
Cipher
Drugs for Herpes Labialis (Oral Herpes) Segment by Type
Aciclovir
Valacyclovir
Famciclovir
Docosanol
Other
Drugs for Herpes Labialis (Oral Herpes) Segment by Application
External Use
Oral
Injection
Drugs for Herpes Labialis (Oral Herpes) Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs for Herpes Labialis (Oral Herpes) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Drugs for Herpes Labialis (Oral Herpes) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs for Herpes Labialis (Oral Herpes).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Drugs for Herpes Labialis (Oral Herpes) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Aciclovir
- Valacyclovir
- Famciclovir
- Docosanol
- Other
Applications
- External Use
- Oral
- Injection
Companies covered
- GSK
- Novartis
- Teva
- Mylan
- Cadila
- Apotex
- Daewoong Pharmaceutical
- Livzon
- Luoxin
- Med shine
- Bayer (Campho Phenique)
- Blistex
- Kelun
- Hikma
- Haiwang
- Carmex
- Cipher
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Drugs for Herpes Labialis (Oral Herpes) by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Aciclovir
- 2.2.3 Valacyclovir
- 2.2.4 Famciclovir
- 2.2.5 Docosanol
- 2.2.6 Other
- 2.3 Drugs for Herpes Labialis (Oral Herpes) by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 External Use
- 2.3.3 Oral
- 2.3.4 Injection
- 2.4 Assumptions and Limitations
3 Drugs for Herpes Labialis (Oral Herpes) Breakdown Data by Type
- 3.1 Global Drugs for Herpes Labialis (Oral Herpes) Historic Market Size by Type (2021-2026)
- 3.2 Global Drugs for Herpes Labialis (Oral Herpes) Forecasted Market Size by Type (2027-2032)
4 Drugs for Herpes Labialis (Oral Herpes) Breakdown Data by Application
- 4.1 Global Drugs for Herpes Labialis (Oral Herpes) Historic Market Size by Application (2021-2026)
- 4.2 Global Drugs for Herpes Labialis (Oral Herpes) Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Drugs for Herpes Labialis (Oral Herpes) Market Perspective (2021-2032)
- 5.2 Global Drugs for Herpes Labialis (Oral Herpes) Growth Trends by Region
- 5.2.1 Global Drugs for Herpes Labialis (Oral Herpes) Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Drugs for Herpes Labialis (Oral Herpes) Historic Market Size by Region (2021-2026)
- 5.2.3 Drugs for Herpes Labialis (Oral Herpes) Forecasted Market Size by Region (2027-2032)
- 5.3 Drugs for Herpes Labialis (Oral Herpes) Market Dynamics
- 5.3.1 Drugs for Herpes Labialis (Oral Herpes) Industry Trends
- 5.3.2 Drugs for Herpes Labialis (Oral Herpes) Market Drivers
- 5.3.3 Drugs for Herpes Labialis (Oral Herpes) Market Challenges
- 5.3.4 Drugs for Herpes Labialis (Oral Herpes) Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Drugs for Herpes Labialis (Oral Herpes) Players by Revenue
- 6.1.1 Global Top Drugs for Herpes Labialis (Oral Herpes) Players by Revenue (2021-2026)
- 6.1.2 Global Drugs for Herpes Labialis (Oral Herpes) Revenue Market Share by Players (2021-2026)
- 6.2 Global Drugs for Herpes Labialis (Oral Herpes) Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Drugs for Herpes Labialis (Oral Herpes) Head Office and Area Served
- 6.4 Global Drugs for Herpes Labialis (Oral Herpes) Players, Product Type & Application
- 6.5 Global Drugs for Herpes Labialis (Oral Herpes) Manufacturers Established Date
- 6.6 Global Drugs for Herpes Labialis (Oral Herpes) Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Drugs for Herpes Labialis (Oral Herpes) Market Size (2021-2032)
- 7.2 North America Drugs for Herpes Labialis (Oral Herpes) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Drugs for Herpes Labialis (Oral Herpes) Market Size by Country (2021-2026)
- 7.4 North America Drugs for Herpes Labialis (Oral Herpes) Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Drugs for Herpes Labialis (Oral Herpes) Market Size (2021-2032)
- 8.2 Europe Drugs for Herpes Labialis (Oral Herpes) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Drugs for Herpes Labialis (Oral Herpes) Market Size by Country (2021-2026)
- 8.4 Europe Drugs for Herpes Labialis (Oral Herpes) Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Drugs for Herpes Labialis (Oral Herpes) Market Size (2021-2032)
- 9.2 Asia-Pacific Drugs for Herpes Labialis (Oral Herpes) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Drugs for Herpes Labialis (Oral Herpes) Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Drugs for Herpes Labialis (Oral Herpes) Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Drugs for Herpes Labialis (Oral Herpes) Market Size (2021-2032)
- 10.2 South America Drugs for Herpes Labialis (Oral Herpes) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Drugs for Herpes Labialis (Oral Herpes) Market Size by Country (2021-2026)
- 10.4 South America Drugs for Herpes Labialis (Oral Herpes) Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Drugs for Herpes Labialis (Oral Herpes) Market Size (2021-2032)
- 11.2 Middle East & Africa Drugs for Herpes Labialis (Oral Herpes) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Drugs for Herpes Labialis (Oral Herpes) Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Drugs for Herpes Labialis (Oral Herpes) Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 GSK
- 12.1.1 GSK Company Information
- 12.1.2 GSK Business Overview
- 12.1.3 GSK Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026)
- 12.1.4 GSK Drugs for Herpes Labialis (Oral Herpes) Product Portfolio
- 12.1.5 GSK Recent Developments
- 12.2 Novartis
- 12.2.1 Novartis Company Information
- 12.2.2 Novartis Business Overview
- 12.2.3 Novartis Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026)
- 12.2.4 Novartis Drugs for Herpes Labialis (Oral Herpes) Product Portfolio
- 12.2.5 Novartis Recent Developments
- 12.3 Teva
- 12.3.1 Teva Company Information
- 12.3.2 Teva Business Overview
- 12.3.3 Teva Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026)
- 12.3.4 Teva Drugs for Herpes Labialis (Oral Herpes) Product Portfolio
- 12.3.5 Teva Recent Developments
- 12.4 Mylan
- 12.4.1 Mylan Company Information
- 12.4.2 Mylan Business Overview
- 12.4.3 Mylan Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026)
- 12.4.4 Mylan Drugs for Herpes Labialis (Oral Herpes) Product Portfolio
- 12.4.5 Mylan Recent Developments
- 12.5 Cadila
- 12.5.1 Cadila Company Information
- 12.5.2 Cadila Business Overview
- 12.5.3 Cadila Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026)
- 12.5.4 Cadila Drugs for Herpes Labialis (Oral Herpes) Product Portfolio
- 12.5.5 Cadila Recent Developments
- 12.6 Apotex
- 12.6.1 Apotex Company Information
- 12.6.2 Apotex Business Overview
- 12.6.3 Apotex Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026)
- 12.6.4 Apotex Drugs for Herpes Labialis (Oral Herpes) Product Portfolio
- 12.6.5 Apotex Recent Developments
- 12.7 Daewoong Pharmaceutical
- 12.7.1 Daewoong Pharmaceutical Company Information
- 12.7.2 Daewoong Pharmaceutical Business Overview
- 12.7.3 Daewoong Pharmaceutical Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026)
- 12.7.4 Daewoong Pharmaceutical Drugs for Herpes Labialis (Oral Herpes) Product Portfolio
- 12.7.5 Daewoong Pharmaceutical Recent Developments
- 12.8 Livzon
- 12.8.1 Livzon Company Information
- 12.8.2 Livzon Business Overview
- 12.8.3 Livzon Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026)
- 12.8.4 Livzon Drugs for Herpes Labialis (Oral Herpes) Product Portfolio
- 12.8.5 Livzon Recent Developments
- 12.9 Luoxin
- 12.9.1 Luoxin Company Information
- 12.9.2 Luoxin Business Overview
- 12.9.3 Luoxin Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026)
- 12.9.4 Luoxin Drugs for Herpes Labialis (Oral Herpes) Product Portfolio
- 12.9.5 Luoxin Recent Developments
- 12.10 Med shine
- 12.10.1 Med shine Company Information
- 12.10.2 Med shine Business Overview
- 12.10.3 Med shine Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026)
- 12.10.4 Med shine Drugs for Herpes Labialis (Oral Herpes) Product Portfolio
- 12.10.5 Med shine Recent Developments
- 12.11 Bayer (Campho Phenique)
- 12.11.1 Bayer (Campho Phenique) Company Information
- 12.11.2 Bayer (Campho Phenique) Business Overview
- 12.11.3 Bayer (Campho Phenique) Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026)
- 12.11.4 Bayer (Campho Phenique) Drugs for Herpes Labialis (Oral Herpes) Product Portfolio
- 12.11.5 Bayer (Campho Phenique) Recent Developments
- 12.12 Blistex
- 12.12.1 Blistex Company Information
- 12.12.2 Blistex Business Overview
- 12.12.3 Blistex Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026)
- 12.12.4 Blistex Drugs for Herpes Labialis (Oral Herpes) Product Portfolio
- 12.12.5 Blistex Recent Developments
- 12.13 Kelun
- 12.13.1 Kelun Company Information
- 12.13.2 Kelun Business Overview
- 12.13.3 Kelun Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026)
- 12.13.4 Kelun Drugs for Herpes Labialis (Oral Herpes) Product Portfolio
- 12.13.5 Kelun Recent Developments
- 12.14 Hikma
- 12.14.1 Hikma Company Information
- 12.14.2 Hikma Business Overview
- 12.14.3 Hikma Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026)
- 12.14.4 Hikma Drugs for Herpes Labialis (Oral Herpes) Product Portfolio
- 12.14.5 Hikma Recent Developments
- 12.15 Haiwang
- 12.15.1 Haiwang Company Information
- 12.15.2 Haiwang Business Overview
- 12.15.3 Haiwang Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026)
- 12.15.4 Haiwang Drugs for Herpes Labialis (Oral Herpes) Product Portfolio
- 12.15.5 Haiwang Recent Developments
- 12.16 Carmex
- 12.16.1 Carmex Company Information
- 12.16.2 Carmex Business Overview
- 12.16.3 Carmex Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026)
- 12.16.4 Carmex Drugs for Herpes Labialis (Oral Herpes) Product Portfolio
- 12.16.5 Carmex Recent Developments
- 12.17 Cipher
- 12.17.1 Cipher Company Information
- 12.17.2 Cipher Business Overview
- 12.17.3 Cipher Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026)
- 12.17.4 Cipher Drugs for Herpes Labialis (Oral Herpes) Product Portfolio
- 12.17.5 Cipher Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst